Brookfield Asset Management Announces Pricing of $600 Million Notes Due 2030 and $400 Million Notes Due 2036 GlobeNewswire November 13, 2025 NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Brookfield Asset Management Ltd. (“BAM”) (NYSE: BAM, TSX: BAM) a leading global alternative asset manager headquartered in New York with over $1 trillion of assets under […]

DPM Metals Reports Record Third Quarter 2025 Financial Results; VareÅ¡ Positioned for Significant Value Creation GlobeNewswire November 13, 2025 TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or the “Company”) announced its operating and financial results for the third quarter and first nine months ended September

Tejon Ranch Co. CEO Issues Letter Ahead of Investor Engagement Event GlobeNewswire November 13, 2025 TEJON RANCH, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Tejon Ranch Co. (the “Company”) (NYSE:TRC), a diversified real estate development and agriculture company, today issued a public letter from President and Chief Executive Officer Matthew Walker to their shareholders, ahead

Peyto Reports Third Quarter Results and Preliminary 2026 Capital Program GlobeNewswire November 13, 2025 CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — Peyto Exploration & Development Corp. (“Peyto” or the “Company”) is pleased to report operating and financial results for the third quarter of 2025 and a preliminary capital budget for 2026. Highlights: Peyto reported

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights GlobeNewswire November 13, 2025 Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patients Multiple SAFEGUARD trial sites activated; on-track to dose first patient by year-end Recent data presented at EASD and IPSAD provide further validation for SAB-142 as

Enthusiast Gaming Reports Q3 2025 Financial Results GlobeNewswire November 13, 2025 Adjusted EBITDA from continuing operations of $1.2 million for the nine months ended September 30, 2025, compared to a loss of $0.1 million in the year ago period Completed sale of Direct Sales Media Business and related creative assets in Q3, resulting in a

Omni-Lite Industries Announces Results of Annual General Meeting GlobeNewswire November 13, 2025 TSXV: OML OTCQX: OLNCF LOS ANGELES, CALIFORNIA, Nov. 13, 2025 (GLOBE NEWSWIRE) — Omni-Lite Industries Canada, Inc. (the “Company” or “Omni-Lite”; TSXV: OML), a designer and manufacturer of precision high performance components for aerospace & defense, transportation, and communication applications is pleased to

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI GlobeNewswire November 13, 2025 The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups

Stardust Power Announces Q3 2025 Financial Results GlobeNewswire November 13, 2025 GREENWICH, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) — Stardust Power Inc. (“Stardust Power” or the “Company”) (Nasdaq: SDST), an American developer of battery-grade lithium carbonate, today announced its results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Updates and Subsequent

Aptose Reports Third Quarter 2025 Results GlobeNewswire November 13, 2025 Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now Being Treated at 160 mg Dose of Tuspetinib SAN DIEGO and TORONTO, Nov. 13, 2025 (GLOBE